ClinicalTrials.gg
RecruitingNCT05218356Updated Oct 2, 2024

Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

A Phase 2 interventional study of Covidir injections and Quantitative PCR SARS-CoV-2 in COVID-19, sponsored by Code Pharma. Recruiting at 5 sites in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Code Pharma · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.

Planned enrollment
163rd of 263
130 · median 205
Started
2022
with 38 others
Phase 2
56 of 317
2 open now
Primary completion
2024-12
later than 18 of 27 live
Registered
253rd of 317
by date

Among the 317 studies in COVID-19 with a site in Brazil, this one is the 163rd largest by planned enrollment of the 263 interventional ones that give a count, is one of 39 that started in 2022, is one of 56 in phase 2, reaches primary completion later than 18 of the 27 other live ones, and was the 253rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in COVID-19 with a site in Brazil, or all of them as a file.
02

Study summary

This is a double-blind, multicentre, multinational study to evaluate the safety and collect preliminary efficacy data of Codivir drug product in 130 hospitalized adults with moderate COVID-19 symptoms. COVID-19 symptoms (fever, cough, myalgia and changes in smell or taste) onset must be within 7 days prior enrolment. Treatment will begin in the hospital, participants will be discharged according to medical decision and continue the treatment until to Day 7 at home and followed up to day 28.

Read the detailed description

eligible hospitalized participants will be recruited to the study and will receive standard of care treatments as well as Codivir or placebo, which will be administered at a dose of 20 mg SC, twice a day, for 7 days. If up to medical decision of the medical staff in the site, the patient should be released before Day 7, site study team will contact the medical monitor of the study to get the instructions. Participants will be followed up to the 28th day via phone contact. The phone visit will be performed to monitor the clinical symptoms, collect adverse events and concomitant medication and provide the patient with additional instructions, if relevant.

If they have progressed well, they will continue the treatment up to Day 7 at home, receiving a nurse's home visit twice a day to administer Codivir and collect vital signs. Participants will be followed up to Day 28 by telemedicine. A doctor will call them periodically to monitor the clinical evolution, collect adverse events, concomitant medication and instruct the participants. In case of unfavorable evolution, the participants will remain hospitalized receiving the appropriate care. The investigator will decide whether or not the investigational medication will continue, considering the participant's health and well-being.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years
  • Male or female
  • SARS-CoV-2 infection indicated by confirmed RT-PCR test
  • Moderate hospitalized COVID-19 (at least two out of three criterias below):

    • Evidence of lower respiratory disease during clinical assessment (cough, fever, difficulty breathing) or imaging (X-rays)
    • Oxygen saturation (SpO2) in room air \< 93%
    • \<30 breaths per minute
  • No signs of hemodynamic decompensation
  • Absence of pregnancy in women of childbearing age
  • Ability to understand and comply with the requirements of the protocol
  • Consent to participate
  • Consent to use at least one highly effective methods (condoms, IUD, oral contraceptives) since the ICF signature and at least 30 days after the study.

Exclusion criteria

Exclusion Criteria:

  • Patients receiving oxygen supplementation except of nasal prongs, nasal intermittent positive pressure ventilation (NIPPV) or high flow nasal cannula (HFNC) that are allowed to be enrolled to the study).
  • Positive RT-PCR test more than 72 hours prior to enrolment.
  • Onset of symptoms more than 7 days prior to enrolment.
  • Participant using drugs that are under clinical investigation in last 30 days.
  • less than 19.9 or greater than 35.
  • Comorbidities such as: other serious infections, active , diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study.
  • Concomitant , or infection.
  • Pregnancy or lactation.
  • Vaccination for any other infection in the 4 weeks prior to enrolment.
  • Any condition that increases the risk of participating in the study, in the opinion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Codivir treatment

    20 mg administrated by subcutaneous (SC) injection, twice a day, for 7 days

    Drug: Covidir injections · Diagnostic Test: Quantitative PCR SARS-CoV-2 · Diagnostic Test: IgM and IgG dosage · Diagnostic Test: Screening Blood tests · Diagnostic Test: Electrocardiogram · Other: NEWS-2 score · Other: WHO score · Other: Physical examination · Other: COVID-19-Related Symptoms assessment

  • Placebo comparator
    Placebo treatment

    Placebo administrated in subcutaneous (SC) injection, twice a day, for 7 days

    Drug: Covidir injections · Diagnostic Test: Quantitative PCR SARS-CoV-2 · Diagnostic Test: IgM and IgG dosage · Diagnostic Test: Screening Blood tests · Diagnostic Test: Electrocardiogram · Other: NEWS-2 score · Other: WHO score · Other: Physical examination · Other: COVID-19-Related Symptoms assessment

Interventions

  • DrugCovidir injections

    administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)

    Also known as: Experimental drug administration

  • Diagnostic testQuantitative PCR SARS-CoV-2

    detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.

  • Diagnostic testIgM and IgG dosage

    lood collection for dosage of Anti SARS-CoV-2 antibodies.

  • Diagnostic testScreening Blood tests

    omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.

  • Diagnostic testElectrocardiogram

    valuation by the principal investigator or assistant physician with a complete physical examination

    Also known as: ECG

  • OtherNEWS-2 score

    assessment of the participant by the NEWS-2 score.

  • OtherWHO score

    assessment of the participant by the score of the World Health Organization.

  • OtherPhysical examination

    evaluation by the principal investigator or assistant physician

  • OtherCOVID-19-Related Symptoms assessment

    will be completed by the study staff member based on patient status and answers.

06

What researchers measure

Primary outcomes

  1. Change in World Health Organization Ordinal Scale for clinical improvement

    change in World Health Organization Ordinal Scale for clinical improvement in the treatment group in comparison with Placebo. the scale min score - 0 and max score - 8. the higher the scores mean a worse outcome

    Time frame: up to 28 days

Secondary outcomes

  1. Change in COVID-19-Related Symptoms score (measured on days 7, 14, 21, 28) in the treatment group in comparison with Placebo).

    Each symptom is scored individually using the following response options and scoring values: Items 1-10: None = 0; Mild = 1; Moderate = 2; and Severe = 3 Items 11 and 12: Not at all = 0; 1-2 times = 1; 3-4 times = 2; 5 or more times = 3 Items 13 and 14: Sense of smell/taste same as usual = 0; Sense of smell/taste less than usual = 1; No sense of smell/taste = 2. he higher the scores mean a worse outcome

    Time frame: up to 28 days

  2. adverse events

    Incidence and severity of adverse events related to the investigational product in the treatment group in comparison with Placebo

    Time frame: up to 28 days

  3. RT-PCR viral load

    Time to decreased RT-PCR viral load in the treatment group in comparison with Placebo

    Time frame: up to 28 days

  4. IgM & IgG anti-SARS-CoV-2

    Evolution of IgM \& IgG anti-SARS-CoV-2 in the treatment group in comparison with Placebo

    Time frame: up to 28 days

07

Study locations

5 of 5 sites recruiting
  • Hospital de Amor
    Paulo Prata, Barretos/SP/BRA 147844-000, Brazil
    Recruiting
  • Infection Control
    Prado, Belo Horizonte/MG/BRA 30.110-063, Brazil
    Recruiting
    • Carlos Ernesto Ferreira Starling, Dr. · Contactcstarling@task.com.br · 55 31 98791-3777
    • Carlos Ernesto Ferreira Starling, Dr. · Contact
  • Instituto Lobus
    Casa de Pedra, Volta Redonda/RJ/BRA 27253-003, Brazil
    Recruiting
  • A2Z Clinical
    Vila Martina, Volta Redonda/RJ/BRA 13271-130, Brazil
    Recruiting
    • Dr. Ricardo Sobhie Diaz, Dr. · Contactrsdiaz@catg.com.br · 55 11 99109-0445
    • Dr. Ricardo Sobhie Diaz, Dr. · Contact
  • Casa de Saude
    Centro, 13015-240, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2024, 35 months after the start.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 35 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Feb 1, 2022
StartActual
Jan 20, 2022
Primary completionEst.
Dec 20, 2024
CompletionEst.
Jul 20, 2025
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05218356
Lead sponsor
Code Pharma
Responsible party
Sponsor
First posted
Feb 1, 2022
Start date
Jan 20, 2022
Primary completion
Dec 20, 2024 (estimated)
Completion
Jul 20, 2025 (estimated)
Last update
Oct 2, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion